|RXII -- USA Stock|| |
USD 1.29 0.07 5.74%
We currently do not have informatin regarding Tamara McGrillen. This executive tanure with RXi Pharmaceuticals Corporation is not currenlty determined.
The company has return on total asset (ROA)
of (74.58) %
which means that it has lost $74.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (187.16) %
meaning that it created substantial loss on money invested by shareholders.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 15 people.RXi Pharmaceuticals Corporation (RXII) is traded on Nasdaq Capital Markets in USA. It is located in 257 Simarano Drive and employs 15 people.
RXi Pharmaceuticals Leadership Team
|Geert Cauwenbergh, President CEO, Director|
|Robert Bitterman, Director|
|Pamela Pavco, Chief Devel. Officer|
|Keith Brownlie, Director|
|Jonathan Freeman, Independent Director|
|Gerrit Dispersyn, Chief Development Officer|
|Curtis Lockshin, Director|
|Paul Dorman, Independent Director|
|Alexey Eliseev, Chief Business Officer|
|Tamara McGrillen, IR Contact Officer|
Stock Performance Indicators
Most of Macroaxis users are at this time bullish on RXi Pharmaceuticals Corporation. What is your perspective on investing in RXi Pharmaceuticals Corporation? Are you bullish or bearish?
Currently Active Assets on Macroaxis